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Abstract: In an open-label, prospective, pharmacokinetic assessment,
we evaluated total drug exposure (area under the curve [AUC]) of
intravenous (IV) ganciclovir (GCV) and oral (p.o.) valganciclovir when
normalized for body surface area (BSA) in pediatric liver (n5 20) and
renal (n5 26) transplant patients Reference doses for IVGCV (200 mg/
m2) and p.o. valganciclovir (520 mg/m2) were based on adult doses, and
adjusted for BSA initially, and BSA and renal function (estimated via
creatinine clearance [CrCL]) thereafter. Renal transplant patients
received GCVon days 1^2, valganciclovir 260 mg/m2 on day 3, and
valganciclovir 520 mg/m2 on day 4. Liver transplant patients received
twice daily GCV from enrollment to day12, and then valganciclovir
twice daily on days 13^14. GCVpharmacokinetics were described using
a population pharmacokinetic approach.Type of solid organ transplant
(kidney or liver) had no effect on GCVpharmacokinetics. Median GCV
exposure following valganciclovir 520 mg/m2 was similar to that with
IV GCV, and to that reported in adults. Patientso5 years of age had
AUC values approximately 50% of those compared with older age
ranges; dosing based on both BSA and CrCL increased drug exposure
in younger patients. A dosing algorithm based on BSA and CrCL























































































































Cytomegalovirus (CMV) is a major cause of morbidity and
mortality in children after solid organ transplantation
(SOT) (1), because many of them are likely to be CMVsero-
negative at the time of transplantation.While the ef¢cacyof
ganciclovir (GCV) for the prevention and treatment of CMV
in SOT recipients is well established in adults (2^4), its use
in the management of CMVdisease is limited by poor oral
(p.o.) bioavailability (5), and thus the need for long-term in-
travenous (IV) administration.
Valganciclovir, the valine ester of GCV, overcomes the
limitations of p.o. GCV and is a convenient alternative to
IVadministration.The 10 -fold higher absolute bioavailabil-
ity of p.o. valganciclovir compared with GCV (5, 6), means
that, in adults, dosing with p.o. valganciclovir 900 mg once
daily provides similar GCVexposure to IV GCV (5 mg/kg/
day) (7 ). However, dosing with valganciclovir tablets may
not be appropriate in some patients because of their inabil-
ity to swallow solids for a variety of reasons. To this end, a
p.o. valganciclovir solution has been developed to accom-
modate these patients that is bioequivalent to the tablet for-
mulation and with a similar safety pro¢le, thus allowing
the 2 p.o. formulations to be interchangeable (8).
No universal rule exists for converting adult drug doses
to doses for children (9). Adjusting according to body
weight or body surface area (BSA) is not always successful
(10, 11). Furthermore, a p.o. solution of valganciclovir would
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also be useful for children unable to swallow tablets or cap-
sules. To ¢ll in this knowledge gap, we designed and con-
ducted 2 independent studies of p.o. valganciclovir
solution and IV GCV in de novo pediatric kidney or liver
transplant recipients. We hypothesized that IV dosing of
GCVand p.o. dosing of valganciclovir, normalized for BSA
in pediatric liver and kidney transplant patients, would
provide similar GCVarea under the curve (AUC) values as
those established for adults. Additionally, we hypothesized
that BSA-normalized p.o. valganciclovir doses would pro-
vided comparable GCVAUC values to BSA-normalized IV
GCVdoses in this population.
Methods
Study design and patient population
Two open-label studies were conducted in 9 US centers (6
renal and 3 liver). Both studies were approved by the Insti-
tutional Review Boards at each institution and written in-
formed consent was provided by patients’ parents or
guardians and assent by the children as appropriate.
Renal study
Children aged 3 months to 16 years considered at risk of de-
veloping CMVdisease who had received their ¢rst kidney-
only transplant were eligible for study entry. Patients were
required to have absolute neutrophil count41000 cells/mL;
platelet count 425,000 cells/mL; hemoglobin 48.0 g/dL;
and stable renal function with creatinine clearance (CrCL)
445 mL/min/1.73 m2 (Schwartz et al. formula [12]). Exclu-
sion criteria included allergic or other significant adverse
reaction to acyclovir, GCV, or valacyclovir; severe, uncon-
trolled diarrhea or evidence of malabsorption; patients
simultaneously participating in another trial, except as
approved by the sponsor; female patients who were lactat-
ing and would not discontinue nursing before study entry;
pregnancy; and liver function impairment of45 times the
upper limit of normal for aspartate aminotransferase
(AST) or alanine aminotransferase (ALT).
Liver study
The criteria for the liver trial were identical to those of the
renal study, with the exception that children at risk of con-
tracting Epstein^Barr virus (EBV) could also be included.
Exclusion criteria were also identical, except for the exclu-
sion of liver function impairment and the inclusion of evi-
dence of graft rejection or antiviral prophylaxis with a




Reference doses were based on adult dosages as follows.
The standard 5 mg/kg IV GCVdose for a 70 kg adult with
a BSA of 1.73 m2 is 350 mg; this corresponds to a pediatric
reference dose of 200 mg/m2.The standard 900 mg dose of
p.o. valganciclovir for an adult with BSA of 1.73 m2 corre-
sponds to a pediatric reference dose of 520 mg/m2.
In both studies, IV GCVand p.o. valganciclovir dosages
were calculated as follows:
Full doseðmgÞ ¼ Reference doseðmg=m2Þ
 BSA of patientðm2Þ;
where BSAwas calculated using Mosteller’s equation (13):
BSAðm2Þ ¼ p½ðheightðcmÞ  weightðkgÞÞ=3600:
In order to estimate the most appropriate dose of p.o. val-
ganciclovir in children an additional dose level of p.o. val-
ganciclovir (260 mg/m2) corresponding to 50% of the
reference p.o. valganciclovir dose was included in the renal
study.
According to renal function
In both studies, the reference doses for both agentswere ad-
justed for reduced renal function based on estimated CrCL,
as outlined in Table 1. CrCL was estimated from serum
creatinine using the Schwartz et al. formula (12):
CrCLðmL=min=1:73m2Þ ¼ ½k heightðcmÞ=
½serum creatinineðmg=dLÞ;
where k 5 0.45 for those aged o2 years, k 5 0.55 for those
aged  2 years too13 years, and for those aged  13
years to  20 years, k 5 0.7 for males and k 5 0.55 for
females.
Drug regimens and procedures
Renal study
Individual study drug dosing lasted for a total of 4 days.
The shorter interval in the renal study compared with the
14 days in the liver study, resulted from the more rapid time
to stability and discharge from the hospital for the renal
transplant patients. Screening assessments were per-
formed in the ¢rst week after transplantation after the sta-
bilization of renal function, followed by 4 consecutive days
of treatment with study drugs, a follow-up visit (day of last
pharmacokinetic sample, 28^32 days post transplant), and
a safety review visit (28 days after cessation of study drug
 4 days). Serum creatinine used to estimate CrCL was
measured on each day of treatment and at the follow-up vis-
it. After stabilization of renal function following transplan-
tation, subjects received treatment once daily between
Pescovitz et al: Valganciclovir pharmacokinetics in pediatric SOT
196 Transplant Infectious Disease 2010: 12: 195^203
7 and 9 a.m. with a single dose of IV GCVon days 1 and 2
and a single dose of p.o. valganciclovir solution of 260 mg/
m2 on day 3 and 520 mg/m2 on day 4. Blood samples for de-
termination of GCV concentrations were collected on dos-
ing-days 2, 3, and 4 as follows: pre-dose (up to 2 h before
dosing), and 1 h (immediately before the end of the infu-
sion), and between 2^3, 5^7, and 10^12 h post dose on day
2; pre-dose, and between 0.25^0.75, 1^3, 5^7, and 10^12 h
post dose on day 3; and pre-dose, and between 0.25^0.75,
1^3, 5^7, 10^12, and 22^24 h post dose on day 4.
Liver study
Screening and enrollment were conducted between days 1
and 4 (day 0 was the day of the transplant); patients re-
ceived study drugs from enrollment up to day14 post trans-
plant.The follow-up and safety reviewswere on days 28^32
and 42  4 post treatment, respectively. Serum creatinine
used to estimate CrCLwas measured on days 11^14. Study
drugs were administered twice daily ^ between 7 and 9
a.m. for the ¢rst dose, and the second as close as possible
to 12 h after the ¢rst dose. However, theAUCwas calculated
using only samples obtained during the 12-h period around
the morning dose of drug.The 24 -h AUCwas calculated us-
ing non-linear mixed e¡ect modeling (NONMEM) assum-
ing once a day dosing.
Patients received treatment with IVGCV, initiated on en-
rollment (days 1^4 after transplantation) and continued to
day 12 post transplant. On days 13 and 14 post transplant,
patients received p.o. valganciclovir solution twice daily.
Blood sampling was conducted on days 12 and 14 as fol-
lows: pre-dose (up to 2 h before dosing), and 1 h (immedi-
ately before the end of the infusion), and between 2^3, 5^7,
and 10^12 h post dose on day12; and pre-dose, and between
0.25^0.75, 1^3, 5^7, and 10^12 h post dose on day14.
Drug administration
In both studies, IVGCVwas given over 1h as a constant rate
infusion. GCV for IV infusion (Cytovenes, Roche, Nutley,
NewJersey, USA) was provided as sterile, lyophilized powder
in sealed vials containing 500mg GCV for reconstitution in
10 mL of saline.Valganciclovir was provided as a strawberry-
£avored 15 g powder blend containing 3 g valganciclovir; it
was reconstituted with 50mL water to give a ¢nal volume
of 60mL; the solution was sweetened with saccharine and
was administered within 15min of a meal. One batch of val-
ganciclovir p.o. solution was used in each study.
Study assessments and procedures
Screening assessment in both studies included a limited
physical examination, laboratory safety tests (hematology,
serum chemistry), and a medical examination including
assessment of concomitant illnesses, laboratory safety
tests, assessment of puberty stage (Tanner stage [14]), preg-
nancy tests for females of child-bearing potential, measure-
ment of serum creatinine, and estimated CrCL. In addition,
the CMV serological status of the graft and recipient was
determined in the renal study, and the CMVand EBV sero-
logical status of the graft and recipient was determined in
the liver study.
Adverse events occurring since consent and medications
to treat these adverse events were also recorded in both
studies.
Drug assay
In each study, venous blood (1mL) was collected into plastic
ethylene diamine tetraacetic acid tubes and centrifuged
(15 min at 1200 g) at 41C within 30 min. Plasma samples
were frozen immediately at  701C pending analysis. The
plasma concentration of GCVwas determined byAnalytico
Medinet (Breda, the Netherlands) following deproteination,
by adding trichloroacetic acid, using a validated speci¢c
liquid chromatography-tandem mass spectrometry meth-
od. GCVwas provided by Ho¡mann La-Roche (Basel, Swit-
zerland). The dynamic range for the quanti¢cation of GCV
was between 0.040 and 20 mg/mL, which was based on 8
different concentration levels (coef¢cient of correlation
 0.99. The overall accuracy and inter-assay variability of
the assay was 98.7^105% and 0.7^12.0%, respectively.
Because of the rapid conversion of valganciclovir to GCV,
plasma valganciclovir concentrations are not detectable,
and were therefore not measured in either study or in-
cluded in the pharmacokinetic model.
Population pharmacokinetic modeling
Pharmacokinetic model
A 2-compartmental model for GCVwas considered appro-
priate based on previous population pharmacokinetic anal-
yses for GCV in adult SOT recipients (7 ). The model
Valganciclovir and ganciclovir dosing based on estimated creatinine
clearance (CrCL)




o40 Patient withdrawn from study
Reference doses were 200mg/m2 for intravenous ganciclovir and 260
or 520mg/m2 for oral valganciclovir solution.
Table1
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parameters were clearance (CL), volume of distribution at
steady state (Vss), intercompartmental clearance (Q), pe-
ripheral volume of distribution (Vperiph), ¢rst-order absorp-
tion (for valganciclovir), lag time, and bioavailability of
GCV from valganciclovir (F1).
NONMEM software (VersionV, Icon, Dublin, Ireland) and
the ¢rst-order estimation methodwere used. NONMEMwas
developed at the University of California, San Francisco as
software for ¢tting non-linear mixed effects (statistical
regression-type) models. The methodology is particularly
useful for population pharmacokinetic analyses and in situ-
ations such as in this trial, where there are few pharmacoki-
netic samples per subject. Inter-subject variability was
assessed using an exponential function. A combined multi-
plicative and additive error model was used for the residual
random effects.
Covariate selectionwas conducted on gender, age, height,
puberty, body weight, BSA, type of SOT (kidney or liver),
serum creatinine, AST, ALT, total bilirubin, and CrCL de-
rived from the Cockroft^Gault formula (CrCLC) (15) and
Schwartz et al. formula (CrCLS) (11). Stepwise generalized
additive modeling in Xpose 3.102 was used initially to se-
lect the covariates to be tested within NONMEM. Then a
comprehensive forward addition and backward procedure
was followed to build the ¢nal covariate model. Model dis-
crimination was based on a decrease in objective function
values and visual inspection of goodness-of-¢t plots.
Pharmacokinetic endpoints
The primary pharmacokinetic parameter in both studies
was the extent of exposure (AUC) to GCVafter administra-
tion of IV GCVand p.o. valganciclovir solution, determined
as the area under the GCV concentration^time curve over
24 h (AUC0 24) using population pharmacokinetic analy-
sis. Population pharmacokinetic analysis was also used to
determine secondary pharmacokinetic parameters, which
included CL; F1;Vss;Vperiph; volume of central compartment
(Vcent); absorption rate constant (Ka); maximumplasma con-
centration (Cmax); and terminal elimination half-life (t1/2). In-
dividual parameters were calculated using individual post
hoc estimates derived from population estimates and the in-
dividual data.
Statistics
No formal statistical tests or sample size calculations were
performed.The planned target recruitment was 24 patients
in the renal study and 20 patients in the liver study. These
sample sizes were deemed adequate to derive the pharma-
cokinetic pro¢le of GCV after administration of IV GCV
and p.o. valganciclovir solution. Descriptive statistics were
used to summarize the pharmacokinetic data.
Results
Renal study
Twenty-six patients were enrolled, aged  5 years (n5 5),
6^11 years (n57 ), and 12^16 years (n514) (Table 2). One
patient withdrew prematurely after refusing treatment
with valganciclovir p.o. solution, having received both
doses of IV GCV. Data for this patient are included in all
but the pharmacokinetic analyses. Two patients had their
dose of study medication reduced because of poor renal
function. The ¢rst patient (13 years old) received 25% of
Demographics and baseline characteristics of patient population
Variable Renal study (n 526) Liver study (n 520)
Male, n (%) 17 (65) 11 (55)
Race,n (%)
Caucasian 13 (50) 18 (90)
Black 5 (19) 2 (10)
Oriental ^ ^
Other 8 (31) ^
Median age (range)
(years)
12 (1^16) 2 (0^16)
Median weight (range)
(kg)
32.4 (10.6^81.6) 11.9 (5.7^56.9)
Median height (range)
(cm)
137.0 (74.0^185.0) 82.5 (59^175)
Mean estimated CrCL
(SD) (mL/min)
109.9 (43.6) 153.4 (75.3)
CMV status,n (%)1
D1 /R1 16 (62) 4 (20)
D1 /R 6 (23) 6 (30)
D /R1 2 (8) 2 (10)
D /R 2 (8) 8 (40)
EBV status, n (%)1,2
D1 /R1 5 (25)
D1 /R 6 (30)
D /R1 2 (10)
D /R 6 (30)
DND/R1 1 (5)
1Enrollment of patients who were donor seronegative/recipient
seronegative for CMV and/or EBV was permitted because all pediatric
patients were considered at risk, regardless of their serotype.
2EBV serological status not determined in study in renal transplant
recipients.
CMV, cytomegalovirus; CrCL, creatinine clearance; D1 , donor
seropositive; D , donor seronegative; EBV, Epstein^Barr virus;
R1 , recipient seropositive; R , recipient seronegative; SD, standard
deviation; ND, not determined.
Table 2
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the BSA-adjusted dose of 200 mg/m2 of IVGCVand 50% of
the BSA-adjusted higher dose of p.o. valganciclovir solu-
tion (520 mg/m2).The second patient (12 years old) received
50% of the BSA-adjusted dose of 200 mg/m2 of IVGCV.
Liver study
In the liver study, 20 patientswere enrolled: aged  5 years
(n515), 6^11 years (n5 2), and 12^16 years (n5 3) (Table
2). One patient with renal function slightly outside of the
45 mL/min/1.73/m2 inclusion criteria (CrCL 5 41.7 mL/
min/1.73 m2) was inadvertently entered into the study; the
subject’s data were included in the analyses. Fifteen pa-
tients completed the study. Five of the 20 patients (all aged
o5 years) were withdrawn.
Pharmacokinetic results
Final pharmacokinetic model (combined patient cohort)
Of the 46 patients enrolled, 43 were included in the pharma-
cokinetic model. One patient from the renal study was ex-
cluded from the pharmacokinetic model because plasma
levels were not recorded. Two patients from the liver study
were withdrawn before receiving study drug and were also
excluded from the pharmacokinetic model.Three other liver
transplant subjects did not complete the entire study but had
suf¢cient data to include in the pharmacokinetic analysis. Of
the 43 patients included in the model, data were included
from a liver transplant recipient for whom GCVplasma con-
centrations only after administration of IV GCV were avail-
able because this patient was withdrawn before p.o.
valganciclovir administration, and from another liver trans-
plant recipient who received p.o. valganciclovir for only1day.
The ¢nal model for GCVplasma concentrations was a 2-
compartmental model with ¢rst-order formation for p.o.
valganciclovir, lag time, and relative bioavailability. Inter-
subject random variability was modeled for Ka, CL,Vss, Q,
and F1 as exponential errors. The residual error consisted
of a multiplicative and an additive error arm.The multipli-
cative error was 29% and the additive error was 0.14 ng/
mL, which is about 3 -fold above the lower limit of quanti¢-
cation (0.04 ng/mL). The population pharmacokinetic pa-
rameters of the ¢nal model are presented in Table 3. The
height of the patient and CrCLC were identi¢ed as statisti-
cally significant covariates for CL,Vss, andVperiph. Neither
age, gender, nor type of organwere significant covariates in
this model. Inspection of the goodness-of-¢t plots did not
show any substantial bias thus indicating that the pharma-
cokinetic parameters were well estimated. There was no
clinically relevant difference in covariate selection between
using the Schwartz and Cockcroft Gault formulae for calcu-
lation of CrCL (Roche data on ¢le).
Individual pharmacokinetic parameters
Summaries of the derived and individual estimated param-
eters from both studies are shown inTables 4 and 5, respec-
tively. AUC0 24 and Cmax were calculated for the doses
of 200 mg/m2 for IV GCV and 520 mg/m2 for p.o. val-
ganciclovir solution. Two subjects had their doses de-
creased per the dosing algorithm (Table 1) and are
included in this analysis. The ¢rst received 25% of the
BSA-adjusted dose of 200 mg/m2 IV GCV, resulting in
an exposure to GCV of 22.96 mg  h/L, This subject also
received 50% of the BSA-adjusted higher dose of p.o.
valganciclovir syrup resulting in a GCV exposure of
58.35 mg  h/L. The second subject received 50% of the
BSA-adjusted dose of 200 mg/m2 of IVGCV, which resulted
in a GCVexposure of 57.36 mg  h/L.
It was shown during modeling that pharmacokinetic val-
ues for the lower dose of 260 mg/m2 of p.o. valganciclovir
solution investigated in the renal study would be half of
those shown inTable 4 for the 520 mg/m2 dose due to linear-
ity in the pharmacokinetics of valganciclovir.
Basic pharmacokinetic (PK) parameters of ganciclovir of the combined ¢nal population PKmodel
Description PK parameter Estimate Standard error of estimate Intersubject CV (%)
Absorption constant Ka (h) 0.42 0.066 16
Bioavailability F1 0.55 0.038 6.9
Lag time Tlag (h) 0.22 0.0096 4.4
Clearance CL (L/h) 5.4 0.29 5.4
Volume of distribution at steady state Vss (L) 20 1.2 6
Peripheral volume Vperiph (L) 15 1 6.7
Intercompartment clearance Q (L/h) 8 1.5 19
Multiple error 0.29 0.034 12
Additive error (ng/mL) 0.14 0.046 33
Table 3
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Across both studies, exposure to GCVwas noticeably low
in very young patients (aged  5 years) for both IV GCV
and the p.o. valganciclovir solution (Table 4). In addition,
in all age groups, exposure to GCV following treatment
with IV GCV was broadly similar to that following treat-
ment with p.o. valganciclovir solution 520 mg/m2. In both
liver and kidney, Cmax values for all ages were comparable,
with means ranging 9.03^12.2 Cmax. Values were notably
lower for p.o. valganciclovir, but also comparable between
age groups/transplant types with means of 5.10^6.9.
Individual estimated pharmacokinetic parameters1 of ganciclovir in pediatric renal or liver transplant recipients by age group
Age group (years)
0^5 6^11 12^16
Renal study n5 4 n57 n514
CL (L/h) 4.71 (3.83^5.23) 4.92 (3.62^8.75) 7.40 (3.39^12.93)
F1 0.44 (0.40^0.59) 0.54 (0.46^0.80) 0.53 (0.42^0.77)
Ka (L/h) 0.80 (0.63^1.92) 0.67 (0.42^1.18) 0.72 (0.16^1.88)
Vcent (L) 7.20 (3.99^7.74) 15.03 (10.87^17.81) 22.07 (9.58^34.83)
Vperiph (L) 5.71 (2.13^10.12) 9.94 (6.91^47.20) 18.84 (5.10^144.30)
Vss (L) 13.19 (6.11^17.29) 24.99 (17.77^64.42) 40.81 (17.85^177.90)
Liver study n513 n52 n5 3
CL (L/h) 4.05 (2.11^7.92) 2.86 (1.88^3.84) 15.1 (11.4^16.8)
F1 0.52 (0.39^0.83) 0.71 (0.7^0.72) 0.64 (0.57^0.72)
Ka (L/h) 0.45 (0.13^0.86) 0.35 (0.23^0.48) 0.42 (0.3^0.52)
Vcent (L) 1.66 (0.45^2.51) 5.74 (5^6.48) 12.8 (12.8^16.8)
Vperiph (L) 5.65 (2.9^7.6) 14.6 (12^17.3) 30.7 (25.1^34.6)
Vss (L) 7.62 (3.35^10.1) 20.4 (17^23.8) 43.5 (37.9^51.4)
1Values are expressed as medians (minimum^maximum).
CL, clearance; F1, bioavailability of ganciclovir from valganciclovir; Ka, absorption rate constant; Vcent, volume of central compartment; Vperiph, volume of
peripheral compartment; Vss, steady-state volume of distribution.
Table 5
Derived pharmacokinetic parameters1 of ganciclovir in pediatric renal or liver transplant recipients following treatment with oral valganciclovir and
intravenous ganciclovir, by age group
Intravenous ganciclovir (200mg/m2) Oral valganciclovir (520mg/m2)
Age group 0^5 years 6^11years 12^16 years 0^5 years 6^11years 12^16 years






















































1Values are expressed as medians (range).
AUC0^24, area under the concentration time curve from 0 to 24 h; Cmax, maximum plasma concentration.
Table 4
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In the renal study, CL increased with age, as did drug ex-
posure. Moreover, GCVexposure based on BSA alone in the
renal study was generally lower in younger children, but
was increased when corrected for both BSA and renal func-
tion (Fig. 1). The very low r value, when adjusting by both
BSA and CrCl, indicates that AUC is no longer correlated
with age, an important improvement in a dosing regimen.
In contrast, in the liver study, there was no clear pattern in
the age-related effect on clearance or exposure of GCV.This
could be, in part, attributed to the skewed distribution of pa-
tients across the age groups in the liver study. In this study,
the clearance of GCVwas markedly lower in the 13 children
aged  5 years than the 3 children aged 12^16 years; how-
ever, it was lower still in the 2 children aged 6^11 years
(Table 5). The t1/2 was shorter in younger children (median
1.65 h) than in those aged 6^11 and 12^16 years (6.80 and
4.35 h, respectively). Similarly, in the renal study, t1/2 in-
creasedwith increasing age; medianvalueswere 3.28 (range
1.97^6.31), 4.41 (range 3.06^12.77 ), and 5.62 (3.32^27.04) in
the 0^5, 6^11, and 12^16 years age groups, respectively.
The estimated bioavailability of GCV from p.o. val-
ganciclovir solution was only slightly lower in the younger
children than the older children in both studies (Table 5);
this suggests that there was essentially no dependence of
F1values on age.
Safety
In both studies, IV GCV and valganciclovir p.o. solution
were generally well tolerated. The majority of treatment-
emergent adverse events were of mild or moderate severity
and were gastrointestinal in nature. There were no deaths
in either study.
Renal study
Treatment-emergent adverse events were reported in 50%
of patients in the IV GCV phase and in 32% of patients in
the p.o. valganciclovir phase. Four patients experienced
treatment-related adverse events; 3 while receiving p.o. val-
ganciclovir solution (nausea n51, vomiting n51, and
headache n5 2), and 1while receiving IVGCV (thrombocy-
topenia). Four severe adverse events were reported, of
which 1 occurred on treatment (sepsis; with valganciclovir
solution). Four patients experienced 6 serious adverse
events, of which 2 occurred on treatment with p.o. val-
ganciclovir but were not considered treatment related.
Liver study
Treatment-emergent adverse eventswere reported in 90%of
patients in the IVGCVphase of the study.There were only 2
adverse events in the p.o. valganciclovir treatment phase,
which were not severe, serious, or treatment related. Three
patients experienced a total of 6 adverse events that were re-
motely or possibly related to treatment with IVGCV (rash in
1 patient, anemia and renal impairment in 1 patient, and
vomiting, diarrhea, and increased hepatic enzymes in 1 pa-
tient). Of 22 severe adverse events, 2 were life threatening (2
occurrences of post-procedural hemorrhage in 1 patient dur-
ing IVGCV treatment and during the o¡-treatment phase of
the study). Ten patients experienced 14 serious adverse
events in the IVGCVphase, of which 2 were related to study
treatment (vomiting and increased hepatic enzymes).
Discussion
The median exposure to GCV in older children receiving
520 mg/m2 p.o. valganciclovir solution (39.88 mg  h/L in
12^16 -year-olds in the renal study) was in agreement with
y = 0.8139 x + 40.386
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Fig. 1. Relationship between age and projected ganciclovir exposure
from oral valganciclovir in patients receiving a renal transplant. Patients
were dosed with study drug according to an algorithm based on (A) body
surface area, and (B) body surface area and renal function.
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that observed in adult patients receiving 900 mg val-
ganciclovir once daily (mean of approximately 46 mg  h/
mL) (5, 7 ). In the renal study, the GCVexposure, based on
BSA alone, was generally low in younger children; drug ex-
posure was increased in this age group when corrected for
both BSA and renal function (estimated via CrCL). The
clear trend of decreasing exposure with younger age shown
in the renal study was not observed in the liver study, pre-
sumably because there were limited number of patients in
the 2 older liver transplant groups. The youngest children
were underexposed to GCV by about 2-fold; this did not ap-
pear to be attributable to a lack of simultaneous adjustment
for age in clearance because clearance of GCVwas lower in
the youngest age groups compared with the oldest age
groups (median 4.7 L/h in 0^5 -year-olds vs. 7.4 L/h in 12^
16 -year-olds in the renal study and 15.1 vs. 4.1 L/h in the
liver study). These results suggest that a dosing algorithm
based on BSA alone is inadequate to deliver similar GCV
exposures across the age ranges investigated in these 2 pe-
diatric studies.
Because the bioavailability of GCV from p.o. val-
ganciclovir solution was essentially independent of age
and the drug is eliminated almost exclusively unchanged
in the urine, we propose that renal function (assessed via
CrCLS) should be included as a standard criterion in addi-
tion to BSA in future dosing algorithms for p.o. val-
ganciclovir in children. Estimated CrCL has been used
previously as a predictor of systemic GCV clearance in a
dosing algorithm in a population pharmacokinetic model
in adult SOT recipients (7 ). An individualized dosing algo-
rithm for p.o. valganciclovir solution or tablets (where
dose 57  BSA  CrCL) has recently been shown in a pe-
diatric population to provide GCV exposures similar to
those obtained in adults, with age and type of SOT having
limited impact on GCV pharmacokinetics. The dosing
schedule used in this report was based on the data pre-
sented in this paper (16).
In our studies, the bioavailability and Cmax of GCV from
p.o. valganciclovir solution was similar to that previously
obtained in adult SOT recipients (44^71% [both studies]
vs. 61% (17 ) and 5^7 mg/L [renal study] vs. 5^6 mg/L (5),
respectively). Previous data have shown that the pharmaco-
kinetics of GCV are generally similar between neonates,
children, and adults (18^21).
Given the short duration of these studies, and the exten-
sive use of concomitant medications, it is dif¢cult to assess
causality or draw conclusions regarding the overall safety
pro¢le.
Significant £uid shifts and ascitic £uid losses can occur
in the ¢rst 2 weeks after liver transplantation, and could
have potentially in£uenced GCV clearance values in the
liver study. However, in our model, the type of SOTwas not
found to be a significant covariate for clearance of the drug.
The dosage was adjusted for reduced renal function
based on estimated CrCL calculated using the Schwartz
et al. formula (CrCLS) (12). The Schwartz et al. formula
mayoverestimate glomerular ¢ltration rate (GFR) in the pe-
diatric population, particularly at GFR levels o60 mL/
min/1.73 m2 (22). Nevertheless, CrCLS has good negative
predictive value when CrCLS is 420 mL/min/1.73 m2 (i.e.,
when CrCLS is420 mL/min/1.73 m2 there is a 95% chance
that GFR measured by iothalamate clearance is 415 mL/
min/1.73 m2) (22). As a baseline CrCL of 445 mL/min/
1.73 m2 was required for enrollment, overestimation of
GFR with the Schwartz formula may be less of a concern
(provided renal function remained stable during the study
period).
The systemic exposure to GCV in pediatric renal or liver
transplant recipients was similar after administration of
p.o. valganciclovir solution (520mg/m2) or IV GCV (200mg/
m2). As a dosing algorithmbased onlyon BSA resulted in un-
der-exposure of younger children, an algorithm including in-
dividually estimated CrCL and BSA (dose57  BSA 
CrCL) is currently being investigated and should provide ad-
equate GCVexposure in pediatric renal or liver transplant re-
cipients for the prevention of CMVdisease.
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